

STATUTORY INSTRUMENTS.

S.I. No. 57 of 2022

MEDICINAL PRODUCTS (PRESCRIPTION AND CONTROL OF SUPPLY) (AMENDMENT) (NO. 2) REGULATIONS 2022

S.I. No. 57 of 2022

MEDICINAL PRODUCTS (PRESCRIPTION AND CONTROL OF SUPPLY) (AMENDMENT) (NO. 2) REGULATIONS 2022

I, STEPHEN DONNELLY, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations:

- 1. (1) These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 2) Regulations 2022.
- (2) The collective citation "the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2022" includes these Regulations.
- 2. In these Regulations "Principal Regulations" means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 of 2003).
- 3. The Eighth Schedule (as amended by Regulation 3 of the Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2022 (S.I. No. 32 of 2022)) to the Principal Regulations is amended by inserting the following entry:

"

Medicinal Product	Form and presentation of product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration	Place of administration
Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)	Dispersion for injection, colourless to slightly yellow, clear to mildly opalescent dispersion free from visible particles in a multidose vial. One dose (0.5 mL) contains 5 micrograms of the SARS-CoV-2 spike protein	Administered intramuscularly	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 18 years of age and older	In accordance with relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Administered as a course of 2 doses (0.5 mL each) at such interval as may be specified	Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.

adjuvanted with Matrix-M Notwithstanding any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a beterologous primary schedule, (b) an additional dose may be administered to immunocumpromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a bouster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (iii) immunocompromi sed persons who are 18 years of age or older and have already received ap frimary vaccine course against Covid-19 and (iii) immunocompromi sed persons who are 18 years of age or older and have already received and and inional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of periorisation of		T	T		T
with Matrix-M Notwithstanding any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromised persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to immunocompromised persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and and have already received and have already received and additional dose of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified	and is			in such	
Notwithstanding any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already or defined and have already or def	adjuvanted				
any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a part of a perton of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received and additional dose of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in suc	with Matrix-M			or guidennes.	
any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a part of a perton of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received and additional dose of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in suc					
any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a part of a perton of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received and additional dose of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in suc				NT / Cd / P	
the contrary in the summary of product characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to independent of the second of the				Notwithstanding	
summary of product characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (d) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (iii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine. in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are go older and have already received an additional dose of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment scoto, pregnancy or otherwise), as may be specified					
characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of ago or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of ago or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of ago or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of ago or older and have already received an additional dose of a Covid-19 vaccine, (ii) in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received aprimary vaccine course against Covid-19, and (ii) inmunocompromi sed persons who are 18 years of age or older and have already received aprimary vaccine recourse against Covid-19, and and additional dose of a covid-19 vaccine, and the persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, and the persons who are all years of age or older and have already received an additional dose of a Covid-19 vaccine, and the persons who are the pers					
administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				(a) a dose may be	
part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine. in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
heterologous primary schedule, (b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(b) an additional dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) minunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (iii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine. (iii) in in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				primary schedule,	
dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (iii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
dose may be administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (iii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of age or older and have already received an additional dose of a Covid-19 vaccine. (ii) in in the value of a covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				(b) an additional	
administered to immunocompromi sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of age or older and have already received an additional dose of a Covid-19 vaccine. (ii) in in the value of a covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
sed persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) minunocompromi sed persons who are 18 years of age or older and have already received and have				administered to	
are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received and have already received and additional dose of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
age or older and have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, (iii) in the volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				sed persons who	
have already received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of age or older and have already received an additional dose of a Covid-19 vaccine. in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
received a primary vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
vaccine course against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				nave already	
against Covid-19, and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
and (c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(c) a booster dose may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				unu	
may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
may be administered to— (i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				(a) a booster dose	
(i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				administered to	
are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
are 18 years of age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				(i) persons who	
age or older and have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
have already received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine. in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
received a primary vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
vaccine course against Covid-19, and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				received a primary	
and (ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(ii) immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				against Covid-19,	
immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				and	
immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
immunocompromi sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
sed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				immunocompromi	
age or older and have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
have already received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
received an additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
additional dose of a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
a Covid-19 vaccine, in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				, accinc,	
at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				in such volumes	
in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				,	
and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified				,	
of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
(whether by reference to age, employment sector, pregnancy or otherwise), as may be specified					
reference to age, employment sector, pregnancy or otherwise), as may be specified				(whether by	
employment sector, pregnancy or otherwise), as may be specified				reference to age,	
sector, pregnancy or otherwise), as may be specified				employment	
may be specified				sector, pregnancy	
in such					
				in such	

		recommendations or guidelines, and subject to informed consent being obtained.	
--	--	--	--

".

4. The Twelfth Schedule (as amended by Regulation 4 of the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 15) Regulations 2021 (S.I. No. 718 of 2021)) to the Principal Regulations is amended by inserting the following entry:

"

Medicinal product	Form and presentation of the product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration
Column 1	Column 2	Column 3	Column 4	Column 5
Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)	Dispersion for injection, colourless to slightly yellow, clear to mildly opalescent dispersion free from visible particles in a multidose vial. One dose (0.5 mL) contains 5 micrograms of the SARS-CoV-2 spike protein and is adjuvanted with Matrix-M	Administered Intramuscularly	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 18 years of age and older	In accordance with relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Administered as a course of 2 doses (0.5 mL each) at such interval as may be specified in such recommendations or guidelines. Notwithstanding any directions to the contrary in the summary of product characteristics— (a) a dose may be administered as part of a heterologous primary schedule, (b) an additional dose may be administered to immunocompromised persons who are 18 years of age or older and have already received a primary

Medicinal product	Form and presentation of the product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration
				vaccine course against Covid-19, and
				(c) a booster dose may be administered to—
				(i) persons who are 18 years of age or older and have already received a primary vaccine course against Covid-19, and
				(ii) immunocompromis ed persons who are 18 years of age or older and have already received an additional dose of a Covid-19 vaccine,
				in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, employment sector, pregnancy or otherwise), as may be specified in such recommendations or guidelines, and subject to informed consent being obtained.

,,



GIVEN under my Official Seal, 15 February, 2022.

STEPHEN DONNELLY, Minister for Health.

EXPLANATORY NOTE

(This note is not part of the Instrument and does not purport to be a legal interpretation.)

These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations 2003.

The purpose of these Regulations is to update the relevant schedules in relation to the COVID-19 vaccines to include the Nuvaxovid vaccine.

These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 2) Regulations 2022.

BAILE ÁTHA CLIATH
ARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR
Le ceannach díreach ó
FOILSEACHÁIN RIALTAIS,
BÓTHAR BHAILE UÍ BHEOLÁIN,
CILL MHAIGHNEANN,
BAILE ÁTHA CLIATH 8,
D08 XAO6

Teil: 046 942 3100 r-phost: publications@opw.ie

DUBLIN
PUBLISHED BY THE STATIONERY OFFICE
To be purchased from
GOVERNMENT PUBLICATIONS,
MOUNTSHANNON ROAD,
KILMAINHAM, DUBLIN 8,
D08 XAO6

Tel: 046 942 3100 E-mail: publications@opw.ie

9 "781399"314558"

€3.00